How to Start-Up 9 Oncology Sites in 9 weeks
Over the last decade, increased competition for finite patient populations in the U.S. have led many drug developers to expand…
The Secret to Oncology Clinical Trial Performance – An Interview with Denise Deakin
In this interview, conducted by Keystone Marketing's Scott Broady, Denise Deakin, Co-Founder & President of Scimega Oncology answers questions about…
Top 5 Questions asked by Directors of Clinical Operations
I sat down recently with three of our Oncology Leads and asked them what questions they hear most often from…
Overcoming Site Challenges in Oncology Trials – An interview with Penny Chipman
In this interview Penny Chipman, Manager of the Clinical Research Program at the Gerald Bronfman Centre for Clinical Research in…
Number of sites needed for a Phase 1A Oncology study
Here is a question raised by a potential client that I thought would be of interest to other. “We are…
Oncology drug reimbursement climate in Canada
Canada remains a prime destination for the expansion of both early and late phase oncology clinical trials due the fact…
Reverse Feasibility in Action – Transcript of interview with Dr. Quincy Chu
In this interview, Dr. Quincy Chu, Medical Oncologist at the Cross Cancer Institute in Edmonton Alberta, discusses the ways in…
Value of Canadian oncology centers for early phase trials – Transcript of interview with Dr. Stephen Welch
Given the increased focus on speed of activation for oncology studies, sponsors are under pressure to select top-performing investigative sites…
How to double your oncology enrolment targets
Back in June of 2011, a leading U.S. biotech company, currently developing multiple therapeutic candidates, was planning a Phase I/II…
How to speed up site start-up by 50%: Part 2 – Contract Negotiation
Like patient consent forms, site Clinical Trial Agreements (CTA) have become increasingly complex, making their review a major roadblock to…